Burkehill Global Management’s Viridian Therapeutics VRDN Stock Holding History
Bought
Maintained
Sold
Other funds holding VRDN
KCM
Burkehill Global Management's VRDN Position: Q3 2026 in Review
Burkehill Global Management held its Viridian Therapeutics (VRDN) position steady in Q3 2026 at 65,000 shares worth $1.34M. The position accounts for 0.06% of the portfolio, ranked #116.
Burkehill Global Management first reported a position in VRDN in Q4 2025 and has held it in 4 quarters since. The position peaked at $2.02M in Q4 2025. 235 funds tracked by Wall St. Rank hold VRDN as of Q3 2026.
- Burkehill Global Management held 65,000 shares of Viridian Therapeutics worth $1.34M as of Q3 2026.
- Burkehill Global Management left its Viridian Therapeutics share count unchanged in Q3 2026.
- Viridian Therapeutics made up 0.06% of Burkehill Global Management's portfolio in Q3 2026, its #116 holding.
- Burkehill Global Management first reported a position in Viridian Therapeutics in Q4 2025 and has held it in 4 quarters since.
- Burkehill Global Management's Viridian Therapeutics position peaked at $2.02M in Q4 2025.
- 235 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q3 2026.
Based on Burkehill Global Management's 13F filing for Q3 2026, filed 16 Nov 2026.